To view them, please see the FDA Archive
The Committee provides advice on scientific, technical, and medical issues concerning drug compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, and, as required, any other product for which the Food and Drug Administration has regulatory responsibility, and make appropriate recommendations to the Commissioner of Food and Drugs.
The Committee shall consist of a core of 12 voting members including the Chair. Members and the Chair are selected by the Commissioner or designee from among authorities knowledgeable in the fields of pharmaceutical compounding, pharmaceutical manufacturing, pharmacy, medicine, and related specialties.
These members will include representatives from the National Association of Boards of Pharmacy (NABP), the United States Pharmacopeia (USP), pharmacists with current experience and expertise in compounding, physicians with background and knowledge in compounding, and patient and public health advocacy organizations. Almost all non-Federal members of this Committee serve as Special Government Employees. The core of voting members may include one or more technically qualified members, selected by the Commissioner or designee, who are identified with consumer interests and are recommended by either a consortium of consumer-oriented organizations or other interested persons. In addition to the voting members, the Committee may include one or more non-voting members who are identified with industry interests.
Takyiah Stevenson, PharmD
Designated Federal Officer (DFO)
Division of Advisory Committee and Consultant Management
Office of Executive Programs
E-mail: [email protected]
FDA Advisory Committee Information Line
(301) 443-0572 (local number)
Please call the Information Line for up-to-date information on meetings.
- FDA Advisory Committee Information Line
- (301-443-0572 in the Washington DC area)
Please call the Information Line for up-to-date information on this meeting.